- Home
- NDLS vs XLO Comparison
NDLS vs XLO Comparison
Compare NDLS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDLS | XLO |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 41.8M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NDLS | XLO |
|---|---|---|
| Price | $4.00 | $0.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 252.1K | ★ 550.3K |
| Earning Date | 04-09-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $493,271,000.00 | $6,344,000.00 |
| Revenue This Year | $2.29 | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $0.50 |
| 52 Week High | $4.37 | $1.18 |
Technical Indicators
Market Signals| Indicator | NDLS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 94.12 | 44.48 |
| Support Level | $0.48 | $0.52 |
| Resistance Level | $0.55 | $0.61 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 90.59 | 53.17 |
Price Performance
Historical ComparisonAbout NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.